VERAXA Biotech AG (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company’s outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030, and an increase in the maximum size of the board of directors from five to seven members.
The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities, and continued development of its BiTAC(R) technology platform and oncology pipeline. Management said the vote reflects strong shareholder support for VERAXA’s strategy of advancing antibody-based cancer therapeutics while pursuing long-term value creation.
This approval is significant as it empowers VERAXA to pursue a more aggressive growth trajectory. The capital band and conditional share capital allow the company to issue shares for acquisitions or partnerships without requiring repeated shareholder votes, streamlining the process for strategic moves. The expanded board size can bring in additional expertise to guide the company through its next phases of clinical development and potential commercialization.
For a company focused on next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs, this financial and governance flexibility is crucial. The BiTAC platform, which is a registered trademark of VERAXA Biotech GmbH, represents a proprietary approach to designing bispecific antibodies that can engage T cells to attack cancer cells. The company’s pipeline includes several candidates in preclinical and clinical stages, targeting solid tumors and hematologic malignancies.
The strong shareholder approval, with over 99.94% in favor, indicates confidence in management’s strategy. This comes at a time when the biotech sector faces challenges in financing, making the ability to access capital markets efficiently a competitive advantage. VERAXA’s ability to now issue shares or warrants without further delay could be critical for funding upcoming clinical trial results or securing partnerships with larger pharmaceutical companies.
For more details on the shareholder meeting results, visit the full press release at https://ibn.fm/qfL87. Additional updates on VERAXA are available in the company’s newsroom at http://ibn.fm/VRXA.
